Overview
UK diagnostics firm's FY 2025 revenue rose 3%, driven by higher-margin products
Adjusted EBITDA for FY 2025 rose nearly 10%, in line with forecasts
Company completed a £5.3 mln share buyback, acquiring 21.15 mln shares
Outlook
EKF expects continued revenue from new fermentation agreement in 2026
Company aims to accelerate transformation of Life Sciences division into CDMO
EKF plans to become #1 in global POC Hematology testing
Result Drivers
HIGHER-MARGIN PRODUCTS - Revenue growth driven by focus on higher-margin product ranges and core operations
POC AND LIFE SCIENCES GROWTH - POC revenues increased by 6.5% and Life Sciences grew by 7.2%
β-HB SALES AND NEW AGREEMENT - β-HB sales improved by 10% and new fermentation development agreement contributed additional revenues
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Adjusted EBITDA
GBP 12.40 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for EKF Diagnostics Holdings PLC is GBp35.00, about 28.7% above its January 26 closing price of GBp27.20
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 18 three months ago
Press Release: ID:nRSa4276Qa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
